Total Refinement Solutions LLC Transitions to Royal Biotek Under $BLEG Portfolio
05 Outubro 2023 - 9:18AM
InvestorsHub NewsWire
Royal Biotek: Pioneering Biotechnology Solutions for a Thriving
Future
Melbourne,
FL -- October 5, 2023 --
InvestorsHub NewsWire -- Total
Refinement
Solutions
LLC,
a
pioneering company in the
field
of
pharmaceutical
biotechnology
and
a
subsidiary
of
Branded
Legacy,
Inc
(OTC.PK: BLEG),
is
excited
to
announce
its
transition
to
operate
under
the
"Doing
Business
As"
(DBA) name,
Royal
Biotek.
This
strategic
rebranding
represents
a
significant
milestone
in
the company's
evolution
and
reflects
its
commitment
to
innovation,
excellence,
and
global recognition within the biotechnology sector.
With
years
of
dedicated
expertise
in
the
development
of
cutting-edge
biopharmaceutical solutions,
Total
Refinement
Solutions
LLC
has
earned
a
reputation
for
its
unwavering commitment
to
scientific
advancement,
quality,
and
customer
satisfaction.
This
transition
to Royal
Biotek
is
designed
to
enhance
our
visibility
and
better align our brand with our mission to create a healthier and
more sustainable future through biotechnology
innovation.
"The
transition
to
Royal
Biotek
marks
an
exciting
new
chapter
in
our
journey,"
said
Dave Oswald,
CEO
of
Branded
Legacy.
"Our
commitment
to
traditional
ecological
knowledge,
new research,
and
providing
innovative
solutions
to
the
pharmaceutical
industry
remains unwavering.
We
believe
that
our
new
name
will
not
only
strengthen
our
brand
but
also
amplify our impact on global healthcare."
Customers,
partners,
and
stakeholders
can
rest
assured
that
this
rebranding
will
not
affect
the company's
day-to-day
operations
or
its
dedication
to
providing
exceptional
products
and services.
The
same
team
of
experts,
with
their
deep
industry
knowledge,
will
continue
to
drive the company forward under the Royal Biotek banner.
Royal Biotek will continue to focus on:
-
Advancing pharmaceutical biotechnology research via Traditional
Ecological Knowledge, (TEK)
-
Developing innovative solutions to address global healthcare
challenges.
-
Maintaining
the highest standards of quality and integrity.
-
Strengthening partnerships with organizations and institutions
worldwide.
The
transition
to
the
Royal
Biotek
name
will
be
implemented
immediately,
and
all
future business
activities
will
be
conducted
under
this
name.
The
company's
official
website
and communication channels will be updated accordingly.
For
more
information
about
Royal
Biotek
and
its
innovative
pharmaceutical
biotechnology solutions, please visit our website at
https://royalbiotek.com.
About Royal Biotek:
Royal
Biotek,
formerly
known
as
Total
Refinement
Solutions
LLC,
and
a
subsidiary
of
Branded Legacy,
Inc.,
is
a
leading
company
in
the
field
of
pharmaceutical
biotechnology.
With
a commitment
to
excellence
and
innovation,
Royal
Biotek is dedicated to developing cutting-edge solutions that
contribute to a healthier and more sustainable future.
About Branded Legacy Inc.
Branded
Legacy
Inc.
is
a
forward-thinking
biotechnology
company
dedicated
to
driving innovation
in
plant-derived
medicines
and
biotechnological
breakthroughs.
The
company's strategic
partnerships
and
milestone
achievements
highlight
its
commitment
to
transforming patient
care
and
contributing
to
the
advancement
of
healthcare
solutions.
More
Information
on the
Website: https://brandedlegacy.com/
Media Contact
Joe Holladay
Branded Legacy
Phone: 321-345-3565
Email:
info@brandedlegacy.com
Website:
https://brandedlegacy.com/
Safe Harbor Statement on Forward-Looking Language:
This
release
includes
forward-looking
statements,
which
are
based
on
certain
assumptions
and reflect
management's
current
expectations.
These
forward-looking
statements
are
subject
to
a number
of
risks
and
uncertainties
that
could
cause
actual
results
or
events
to
differ
materially
from current
expectations.
Some
of
these
factors
include
general
global
economic
conditions;
general industry
and
market
conditions
and
growth
rates;
uncertainty
as
to
whether
our
strategies
and business
plans
will
yield
the
expected
benefits;
increasing
competition;
availability
and
cost
of capital;
the
ability
to identify and develop and achieve commercial success; the level
of expenditures necessary
to maintain and improve the quality of services; changes in the
economy; changes in laws and
regulations,
includes
codes
and
standards,
intellectual
property rights, and tax matters; or other matters
not
anticipated;
our
ability
to
secure
and
maintain
strategic
relationships
and
distribution agreements.
Dilution,
if
any,
would
be
for
the
purposes
of
management
taking
stock
in
lieu
of
cash salary.
The
company
disclaims
any
intention
or
obligation
to
update
or
revise
any
forward-looking statements,
whether
as
a
result
of
new
information,
future
events,
or
otherwise.
Additionally,
this press
release
that
is
not
statements
of
historical
fact
may
be
considered
to
be
forward-looking statements.
Written
words
such
as
"may,"
"will,"
"expect,"
"believe,"
"anticipate,"
"estimate," "intends,"
"goal,"
"objective,"
"seek,"
"attempt,"
or
variations
of
these
or
similar
words,
identify forward-looking
statements.
By
their
nature,
forward-looking
statements
and
forecasts
involve
risks and
uncertainties
because
they
relate
to
events
and
depend
on
circumstances
that
will
occur in the near future.
Branded Legacy (PK) (USOTC:BLEG)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Branded Legacy (PK) (USOTC:BLEG)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
